Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-07-26 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司2021年第一次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as the "2021 First Extraordinary General Meeting (EGM) Meeting Materials" of Changchun Baike Biotechnology Co., Ltd. It contains detailed meeting notices, agenda, and proposals to be discussed and voted on at the shareholders meeting. The content includes descriptions of the meeting procedures, voting rights, and specific proposals such as a licensing cooperation agreement and amendments to the company's information disclosure management system. The document is clearly a set of materials prepared for a shareholders meeting, not a report or announcement of results. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement but the actual meeting materials. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or Extraordinary General Meeting.
2021-07-26 Chinese
中信证券股份有限公司关于长春百克生物科技股份公司关联交易事项的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding a licensing cooperation agreement and related party transaction involving Changchun Baike Biotechnology Co., Ltd., Changchun High-tech Industry (Group) Co., Ltd., and Guangzhou Si'anxin Biotechnology Co., Ltd. It includes extensive information about the transaction, the parties involved, the licensing technology, financial terms, risk factors, and the necessity and impact of the transaction. The document is lengthy (15,000 characters) and contains substantive content about the transaction and its financial and operational implications. It is not a brief announcement or a certification, nor is it a transcript or presentation. The content focuses on a capital/financing update related to a licensing agreement and associated payments and investments. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-07-14 Chinese
长春百克生物科技股份公司第四届监事会第八次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at a supervisory board meeting of Changchun Baike Biotechnology Co., Ltd. It discusses approval of adjustments to the use of raised funds and replacement of self-raised funds with raised funds. The document is short (881 characters) and primarily reports on meeting decisions rather than providing detailed financial data or full reports. It does not contain financial statements or detailed analysis, nor is it a report publication announcement. The content relates to capital management and fundraising usage but is a meeting resolution announcement rather than a financing update report. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a regulatory announcement about supervisory board decisions on fundraising usage without detailed financial data or report content.
2021-07-12 Chinese
长春百克生物科技股份公司关于调整募集资金投资项目拟投入募集资金金额的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Changchun Baike Biotechnology Co., Ltd. regarding adjustments to the amounts of funds raised to be invested in specific projects. It details the original and adjusted investment amounts for various projects funded by the company's initial public offering (IPO) proceeds. The document includes board and supervisory committee approvals, independent director opinions, and sponsor institution verification. It is a formal announcement about changes in the use of raised capital, not a full financial report or audit. The document length is 3253 characters, which is relatively short and focused on a specific capital allocation update. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-07-12 Chinese
长春百克生物科技股份公司第四届董事会独立董事关于第四届董事会第十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific board meeting agenda item about a licensing cooperation agreement. It discusses the legality, fairness, and strategic alignment of the transaction. There is no financial data, no full report, no earnings or audit information, and no regulatory certification. The content is related to board/management information, specifically opinions on board meeting matters. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and focused on management/board opinion, not a full report or announcement.
2021-07-12 Chinese
长春百克生物科技股份公司第四届董事会独立董事关于第四届董事会第十四次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion statement from independent directors regarding a specific board meeting agenda item about a licensing cooperation agreement. It includes their review and approval before the board meeting. There is no financial data, no report publication, no voting results, and no mention of regulatory filings or certifications. The content relates to board-level approval and management oversight of a transaction, which fits the category of Board/Management Information (MANG). The document length is short and focused on management/board approval rather than a full report or announcement.
2021-07-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.